Systematic review: does concurrent therapy with 5‐ASA and immunomodulators in inflammatory bowel disease improve outcomes?

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2008.03915.xPMID 19077129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

  2016cited by this paper
• Crohn’s Disease and Colorectal Cancer

  2011cited by this paper
• Erratum: Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

  2010cited by this paper
• Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

  2010cited by this paper
• Salazopyrin, a new sulfanilamide preparation. A. Therapeutic Results in Rheumatic Polyarthritis. B. Therapeutic Results in Ulcerative Colitis. C. Toxic Manifestations in Treatment with Sulfanilamide Preparations.

  2009cited by this paper
• Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

  2008cited by this paper
• European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.

  2008cited by this paper
• Review article: evolving concepts in treatment and disease modification in ulcerative colitis

  2008cited by this paper
• Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase.

  2008cited by this paper
• Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

  2008cited by this paper
• PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells.

  2008cited by this paper
• Predictors of Medication Adherence in Inflammatory Bowel Disease

  2007cited by this paper
• 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint.

  2007cited by this paper
• Risk Factors for Colorectal Neoplasia in Inflammatory Bowel Disease: A Nested Case–Control Study From Copenhagen County, Denmark and Olmsted County, Minnesota

  2007cited by this paper
• 5‐Aminosalicylic acid (mesalazine) use in Crohn's disease: A survey of the opinions and practice of Australian gastroenterologists

  2007cited by this paper
• Risk of Intestinal Cancer in Inflammatory Bowel Disease: A Population-Based Study From Olmsted County, MinnesotaJess T, Loftus EV Jr, Velayos FS, et al (Herlev Univ Hosp, Denmark; Mayo Clinic College of Medicine, Rochester, Minn) Gastroenterology 130:1039–1046, 2006§

  2007cited by this paper
• Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.

  2007cited by this paper
• Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn’s disease

  2007cited by this paper
• Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease.

  2007cited by this paper
• Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.

  2007cited by this paper
• Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

  2007cited by this paper
• Biological therapies in inflammatory bowel disease: top-down or bottom-up?

  2007cited by this paper
• Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.

  2006cited by this paper
• Increasing Incidences of Inflammatory Bowel Disease and Decreasing Surgery Rates in Copenhagen City and County, 2003–2005: A Population-Based Study from the Danish Crohn Colitis Database

  2006cited by this paper
• Systematic review: adherence issues in the treatment of ulcerative colitis

  2006cited by this paper
• European evidence based consensus on the diagnosis and management of Crohn’s disease: current management

  2006cited by this paper
• 5-Aminosalicylate Use and Colorectal Cancer Risk in Inflammatory Bowel Disease: A Large Epidemiological Study

  2006cited by this paper
• Review article: thiopurines in inflammatory bowel disease

  2006cited by this paper
• Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study.

  2006cited by this paper
• Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease

  2006cited by this paper
• Risk factors for ulcerative colitis‐associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: Results of a population‐based study

  2006cited by this paper
• Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity.

  2006cited by this paper
• 5‐Aminosalicylate therapy is associated with higher 6‐thioguanine levels in adults and children with inflammatory bowel disease in remission on 6‐mercaptopurine or azathioprine

  2006cited by this paper
• Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota.

  2006cited by this paper
• Review article: can post‐operative recurrence in Crohn's disease be prevented?

  2006cited by this paper
• Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells

  2006cited by this paper
• Meta‐analysis: colorectal and small bowel cancer risk in patients with Crohn's disease

  2006cited by this paper
• Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ

  2005cited by this paper
• Mesalazine improves replication fidelity in cultured colorectal cells.

  2005cited by this paper
• Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery

  2005cited by this paper
• 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

  2005cited by this paper
• A rare cause of diuretic refractory ascites

  2005cited by this paper
• The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients

  2005cited by this paper
• Effect of 5-Aminosalicylate Use on Colorectal Cancer and Dysplasia Risk: A Systematic Review and Metaanalysis of Observational Studies

  2005cited by this paper
• Polypharmacy and Crohn's disease

  2005cited by this paper
• INFECTION, INFLAMMATION, AND GASTROINTESTINAL CANCER

  2005cited by this paper
• Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease.

  2005cited by this paper
• Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: Mechanistic aspects and antioxidant activity

  2005cited by this paper
• From the authors

  2005cited by this paper
• Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County.

  2004cited by this paper
• Guidelines for the management of inflammatory bowel disease in adults

  2004cited by this paper
• A Prospective Randomized Observer-Blind 2-Year Trial of Azathioprine Monotherapy versus Azathioprine and Olsalazine for the Maintenance of Remission of Steroid-Dependent Ulcerative Colitis

  2004cited by this paper
• Advances in the treatment of Crohn's disease.

  2004cited by this paper
• Pharmacokinetics of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease: Implications for Therapy

  2004cited by this paper
• Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.

  2004cited by this paper
• Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.

  2004cited by this paper
• Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.

  2004cited by this paper
• Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

  2004cited by this paper
• Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

  2004cited by this paper
• How effective are the usual treatments for ulcerative colitis?

  2004cited by this paper
• Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?

  2003cited by this paper
• Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.

  2003cited by this paper
• Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells.

  2003cited by this paper
• Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease

  2002cited by this paper
• Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

  2001cited by this paper
• A 10‐year survey of inflammatory bowel diseases—drug therapy, costs and adverse reactions

  2001cited by this paper
• The risk of colorectal cancer in ulcerative colitis: a meta-analysis

  2001cited by this paper
• Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy

  2001cited by this paper
• A systematic review of the associations between dose regimens and medication compliance.

  2001cited by this paper
• Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease.

  2000cited by this paper
• Erratum: Olsalazine and 6-mercaptopurine-related bone marrow suppression: A possible drug-drug interaction (Clinical Pharmacology and Therapeutics (1997) 62 (464-475))

  2000cited by this paper
• Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group.

  1999cited by this paper
• Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.

  1999cited by this paper
• Azathioprine for maintaining remission of Crohn's disease.

  1998cited by this paper
• Ulcerative colitis practice guidelines in adults

  1997cited by this paper
• Olsalazine and 6‐mercaptopurine‐related bone marrow suppression: A possible drug‐drug interaction

  1997cited by this paper
• Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis.

  1996cited by this paper
• Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.

  1995cited by this paper
• Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential

  1995cited by this paper
• A controlled double blind study of azathioprine in the management of Crohn's disease.

  1995cited by this paper
• Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis.

  1994cited by this paper
• Crohn's disease and colorectal cancer.

  1994cited by this paper
• A population based study

  1993cited by this paper
• Sulfasalazine Revisited

  1993cited by this paper
• Colorectal cancer risk and mortality in patients with ulcerative colitis.

  1992cited by this paper
• Ulcerative Colitis and Colorectal Cancer

  1991cited by this paper
• Ulcerative colitis and colorectal cancer. A population-based study.

  1990cited by this paper
• Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres.

  1988cited by this paper
• Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.

  1980cited by this paper
• An experiment to determine the active therapeutic moiety of sulphasalazine.

  1977cited by this paper
• A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)

  1973cited by this paper
• Controlled trial of sulphasalazine in the treatment of ulcerative colitis

  1964cited by this paper
• Comparison of Corticosteroid and Sulphasalazine Therapy in Ulcerative Colitis

  1962cited by this paper
• Sulphasalazine and salicylazosulphadimidine in ulcerative colitis.

  1962cited by this paper
• The sigmoidoscopic picture of chronic ulcerative colitis (non-specific)

  1925cited by this paper

• Management of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation

  2025cites this paper
• Comparison of Effects on 6-Thioguanine Nucleotides According to Mesalazine Formulation in Pediatric Patients with Ulcerative Colitis.

  2025cites this paper
• “Remodeling the intestinal immune microenvironment”: immune regulation and tissue regeneration by mesenchymal stem/stromal cells in the repair microenvironment of inflammatory bowel disease

  2025cites this paper
• Navigating Combination Therapy in IBD: from Rationale and Evidence To Practical Applications

  2025cites this paper
• Northern Jiangsu People's Hospital.

  2023cites this paper
• Prospects of new targeted nanotherapy combining liponiosomes with berberine to combat colorectal cancer development: an in vivo experimental model.

  2023cites this paper
• Enhancement of antioxidant and anti-inflammatory activities of flavonoid primuletin in DSS induced colitis in C57BL/6 mice

  2022cites this paper
• Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives

  2022cites this paper
• Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review

  2022cites this paper
• Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease

  2022cites this paper
• Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease

  2021cites this paper
• Continued 5ASA use after initiation of anti‐TNF or immunomodulator confers no benefit in IBD: a population‐based study

  2021cites this paper
• Malignancy risk in individuals with familial adenomatous polyposis receiving biologics and immunomodulators

  2021cites this paper
• Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

  2020cites this paper
• Aminosalicylate withdrawal following escalation to immunomodulators or biologics in ulcerative colitis: cost saving, convenient and does not compromise efficacy

  2020cites this paper
• Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Thiopurines

  2019cites this paper
• Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation

  2019cites this paper
• A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease

  2019cites this paper
• Systematic review with meta‐analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies

  2019cites this paper
• Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.

  2018cites this paper
• Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease

  2018cites this paper
• Etude de l’activité anti-inflammatoire intestinale des huiles de Linum usitatissimum.

  2018cites this paper
• Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition

  2018cites this paper
• No Benefit of Concomitant 5‐Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials

  2018cites this paper
• Beta-Glucan based temperature responsive hydrogels for 5-ASA delivery.

  2018cites this paper
• Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease.

  2018cites this paper
• Chinese consensus on the prevention of colorectal cancer (2016, Shanghai)

  2017cites this paper
• Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era

  2017cites this paper
• Novel levan and pNIPA temperature sensitive hydrogels for 5-ASA controlled release.

  2017cites this paper
• Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project

  2016cites this paper
• Optimalisation of conventional therapies in inflammatory bowel disease: Old wine in new bottles

  2016influential citation
• АНЕМИИ ПРИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЯХ КИШЕЧНИКА (обзор литературы)

  2016cites this paper
• Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease

  2016cites this paper
• Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de tiopurinas en la enfermedad inflamatoria intestinal

  2015cites this paper
• ATIONS OF THIOPURINES IN THE TREATMENT OF INFL AMMATORY BOWEL DISEASE

  2015cites this paper
• ow thiopurines are used for the treatment of inflammatory bowel iseases : An Italian survey

  2015cites this paper
• How thiopurines are used for the treatment of inflammatory bowel diseases: an Italian survey.

  2015cites this paper
• European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases.

  2015cites this paper
• Optimisation de la réponse aux thiopurines par la pharmacogénétique : approches in vitro et cliniques

  2014influential citation
• Chemoprevention of Colorectal Cancer

  2014cites this paper
• 5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-Analysis

  2014cites this paper
• Use of thiopurines in inflammatory bowel disease: Safety issues.

  2014cites this paper
• Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.

  2013cites this paper
• Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD.

  2013cites this paper
• Immunomodulatory drugs: Oral and systemic adverse effects

  2013cites this paper
• Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines

  2012cites this paper
• Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease

  2012cites this paper
• Preclinical Cancer Chemoprevention Studies Using Animal Model of Inflammation-Associated Colorectal Carcinogenesis

  2012cites this paper
• Interaction of mesalasine (5-ASA) with translational initiation factors eIF4 partially explains 5-ASA anti-inflammatory and anti-neoplastic activities.

  2011cites this paper
• Azathioprine in ulcerative colitis: Why, when, how and how long to use it

  2011cites this paper
• Treatment of inflammatory bowel disease: medical and surgical aspects

  2011cites this paper
• Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 – Ergebnisse einer Evidenzbasierten Konsensuskonferenz

  2011cites this paper
• Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting.

  2011cites this paper
• Thiopurine immunomodulators in ulcerative colitis: moving forward with current evidence.

  2011cites this paper
• Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease

  2011cites this paper
• Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8‐year intercept cohorts

  2010cites this paper
• A HYBRID APPROACH FOR TRANSLATIONAL RESEARCH

  2010cites this paper
• Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies

  2010influential citation
• Inflammatory Bowel Disease as a Risk Factor for Colorectal Cancer

  2010cites this paper
• Decision-making in ileocecal Crohn’s disease management: surgery versus pharmacotherapy

  2010cites this paper
• Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice

  2010cites this paper
• On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.

  2009cites this paper
• Colorectal cancer in inflammatory bowel disease

  2009cites this paper
• Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease.

  2009cites this paper
• Update in inflammatory bowel disease.

  2009cites this paper
• Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine

  2009cites this paper
• Recent Publications on Medications and Pharmacy

  2009cites this paper
• An investigation of medication adherence to 5‐aminosalicylic acid therapy in patients with ulcerative colitis, using self‐report and urinary drug excretion measurements

  2009cites this paper
• Recent Publications on Medications and Pharmacy

  2009cites this paper
• Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy

  2007cites this paper